Anders Heijl

A New SITA Perimetric Threshold Testing Algorithm: Construction and a Multicenter Clinical Study.

Mean (standard deviation) test times were 171.9 (45.3) seconds for SITA Faster, 247.0 (56.7) for SITA Fast, and 369.5 (64.5) for SITA Standard (P < .001).

Screening for Open-Angle Glaucoma and Its Effect on Blindness.

The results suggest that population screening may reduce bilateral low vision and blindness caused by glaucoma by approximately 50%.

False Positive Responses in Standard Automated Perimetry.

Across 3 different standard automated perimetry thresholding algorithms, FP rates showed only weak associations with visual field test results, except in severe glaucoma.

Long-term Impact of Immediate Versus Delayed Treatment of Early Glaucoma: Results From the Early Manifest Glaucoma Trial.

At study end, percentages of eyes with VI or blindness were slightly higher in the treated group than in the untreated control group, 12.1% vs 11.0%, and 9.4.% vs 6.1% respectively, as were subjects with VI in at least one eye, 19.5% vs 18.7%.

Detection of glaucoma progression by perimetry and optic disc photography at different stages of the disease: results from the Early Manifest Glaucoma Trial.

In the EMGT material on eyes with manifest open-angle glaucoma, the initial progression was detected much more often in the visual field series than in the optic disc photographs at all stages of disease.

Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study.

Intensive treatment led to considerably greater IOP reduction than mono-therapy.

Making a Correct Diagnosis of Glaucoma: Data From the EMGT.

A diagnosis made applying strict criteria to 2 initial visual field tests, supported by optic disc findings if visual field findings were borderline, was almost always correct.

The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data.

Glaucoma Intensive Treatment Study is a clinical trial in which two groups of patients randomized to different initial intensities of IOP-reducing treatment are being compared with regard to rate of visual field progression and prediction…

The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial.

The rate of disease progression was significantly slower in the multi-treated patients than in the mono-treated patients. Further follow-up will show whether this difference is sustained over time.

Predicting undetected glaucoma according to age and IOP: a prediction model developed from a primarily European-derived population.

We created a model estimating the combined effect of IOP and age on the likelihood of undetected glaucoma.

Intraocular Pressure Lowering Effect of Latanoprost as First-line Treatment for Glaucoma.

To the best of our knowledge, this paper is the first to report the IOP-reducing effect of latanoprost treatment at all untreated IOP levels in newly detected glaucoma patients.

Ageing and glaucoma progression of the retinal nerve fibre layer using spectral-domain optical coherence tomography analysis.

No significant differences in change of cpRNFL thickness between visits were found when comparing healthy subjects with glaucoma patients.

Laser trabeculoplasty in newly diagnosed multi-treated glaucoma patients.

Success of LTP was highly dependent on the IOP level prior to LTP treatment.

Long-term follow-up of laser trabeculoplasty in multi-treated glaucoma patients.

LTP performed in multi-treated patients may provide a useful IOP reduction that is maintained over several years.

Estimating the Length of the Preclinical Detectable Phase for Open-Angle Glaucoma.

The mean PCDP was similar for both methods of analysis, approximately 10 years. A mean PCDP of 10 years found in the current study allows for screening with reasonably long intervals, eg, 5 years.

Threat to fixation and vision-related quality of life in early open-angle glaucoma - results from the Glaucoma Intensive Treatment Study.

The presence of TTF did not influence VRQoL, as measured by the NEI-VFQ-25, in this relatively large group of patients with mainly early glaucoma.

Lifetime Risk of Visual Impairment Resulting from Glaucoma in Patients Initially Followed up for Elevated Intraocular Pressure.

Although the investigated patients showed elevated IOP and at least 1 additional glaucoma risk factor (i.e., they were high-risk patients), only a relatively small proportion of the patients with glaucoma demonstrated visual impairment.

The Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development.

In the overall analysis, the visual field outcomes were not overwhelmingly better in the multi-treatment group, but post hoc analysis showed definite benefit in patients with higher untreated IOP.

If we don't change direction soon, we'll end up where we're going: a description of the SSY Engine.

This led to the creation of the SSY (Save Sight Years) concept and later the SSY engine, which is a practical application of this model in the form of a web application.

New Finnish and Swedish glaucoma guidelines.

Impact of mono- or multitherapy on ocular surface health and quality of life after 5 years of follow-up in the Glaucoma Intensive Treatment Study (GITS).

We found no differences in objective or subjective impact on ocular surface between the two randomization arms.

Corrigendum to "The Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development" [Am J Ophthalmol 2024;266:274-288].

Response to Comment on: Long-term Impact of Immediate Versus Delayed Treatment of Early Glaucoma: Results From the Early Manifest Glaucoma Trial.

Lack of Visual Field Improvement After Initiation of Intraocular Pressure Reducing Treatment in the Early Manifest Glaucoma Trial.

Observed visual field changes among glaucoma patients receiving initial IOP-reducing therapy were not significantly different to changes seen in patients who received no treatment.

Structural and Functional Progression in the Early Manifest Glaucoma Trial.

In eyes with manifest glaucoma, progression in the visual field was detected first more than 4 times as often as progression in the optic disc.

Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up.

Our results support the widespread, albeit arbitrary, use of a better-eye visual field of <50% as an important threshold for a significant reduction in VRQOL.

Reply: To PMID 25537196.

Threat to fixation at diagnosis and lifetime risk of visual impairment in open-angle glaucoma.

Including TTF in the assessment of risk for glaucoma blindness did not add any important information when the stage of VFL was taken into account.